title: The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean.
abstract: rs1127354, rs7270101) gene cause ITPA deficiency and protect against the hemolytic toxicity of ribavirin. We investigated the clinical significance of ITPA variants in Korean patients treated with pegylated interferon (PEG-IFN) plus ribavirin. Of the 133 patients, 108 were CC and 25 were non-CC at rs1127354 (groups A and B, respectively). On the other hand, at rs7270101 all 133 were AA. The mean values of Hemoglobin (Hgb) after 4, 8, and 12 weeks of treatment in groups A and B were 12.2 and 14.0, 11.8 and 13.2, and 11.5 and 12.9, respectively (P=0.001, 0.036, 0.036). Sustained virologic response (SVR) was achieved in 67.8% (40/59) of genotype 1 patients and in 75% (27/36) of non-genotype 1 patients. Regarding ITPA variants, SVR was achieved by 66% and 80% of genotype 1 (P=0.282), and by 78% and 71% (P=0.726) of non-genotype 1. SVR was not significantly different in groups A and B. In conclusion, non-CC at rs1127354 without involvement of rs7270101 is strongly associated with protection from ribavirin-induced anemia, however, ITPA genotype is not associated with SVR.
authors: Division of Gastroenterology, Department of Internal Medicine, Gachon University, Gil Medical Center, Incheon, Korea.
authors: Ju Seung
authors: JS
authors: Kim
authors: Sung-Min
authors: SM
authors: Ahn
authors: Young Kul
authors: YK
authors: Jung
authors: Oh Sang
authors: OS
authors: Kwon
authors: Yun Soo
authors: YS
authors: Kim
authors: Duck Joo
authors: DJ
authors: Choi
authors: Ju Hyun
authors: JH
authors: Kim
mesh_terms: D000328:Adult; D000483:Alleles; D000998:Antiviral Agents / Q000627:therapeutic use; D044466:Asian People / Q000235:genetics*; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D006454:Hemoglobins / Q000032:analysis*; D006461:Hemolysis; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000235:genetics*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D007372:Interferons; D007378:Interleukins / Q000235:genetics; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011755:Pyrophosphatases / Q000235:genetics*; D011994:Recombinant Proteins / Q000627:therapeutic use; D056910:Republic of Korea; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome; D000097630:Inosine Triphosphatase; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D006454:Hemoglobins; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D011092:Polyethylene Glycols; D011755:Pyrophosphatases; D011994:Recombinant Proteins; D012254:Ribavirin; D000097630:Inosine Triphosphatase; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C100416:peginterferon alfa-2a
keywords: Anemia; Hepatitis C, Chronic; IL28B; ITPA; Ribavirin
references: J Hepatol. 2009 Feb;50(2):402-11
references: 19091439
references: Lancet. 1998 Jan 10;351(9096):83-7
references: 9439491
references: J Hepatol. 2006;44(1 Suppl):S19-24
references: 16356583
references: Gastroenterology. 2010 Oct;139(4):1181-9
references: 20547162
references: PLoS Comput Biol. 2011 Feb 03;7(2):e1001072
references: 21304937
references: Lancet. 2001 Sep 22;358(9286):958-65
references: 11583749
references: Gastroenterology. 2007 Jan;132(1):103-12
references: 17241864
references: Hepatol Res. 2010 Nov;40(11):1063-71
references: 20977565
references: J Gastroenterol. 2004 Jul;39(7):668-73
references: 15293138
references: Clin Gastroenterol Hepatol. 2007 Jan;5(1):124-9
references: 17196435
references: Curr Med Chem. 2006;13(27):3351-7
references: 17168855
references: Nature. 2010 Mar 18;464(7287):405-8
references: 20173735
references: J Korean Med Sci. 2005 Dec;20(6):985-8
references: 16361809
references: J R Soc Med. 2004 May;97(5):223-5
references: 15121811
references: Hepatology. 2000 Apr;31(4):997-1004
references: 10733558
references: Clin Mol Hepatol. 2012 Dec;18(4):360-7
references: 23323251
references: Am J Gastroenterol. 2006 Apr;101(4):842-7
references: 16494584
references: Gastroenterology. 2010 Feb;138(2):513-21, 521.e1-6
references: 19861128
references: Pharmacogenomics. 2007 Sep;8(9):1221-8
references: 17924837
references: Clin Mol Hepatol. 2012 Sep;18(3):272-8
references: 23091807
references: Liver Int. 2009 Jan;29 Suppl 1:74-81
references: 19207969
references: J Hepatol. 2005 Oct;43(4):590-8
references: 16237783
references: Hepatology. 2011 Feb;53(2):415-21
references: 21246582
references: N Engl J Med. 2002 Sep 26;347(13):975-82
references: 12324553
references: Gastroenterology. 2010 Oct;139(4):1190-7
references: 20637204
references: Biol Pharm Bull. 2009 Nov;32(11):1940-2
references: 19881314
references: Gastroenterology. 2002 Oct;123(4):1061-9
references: 12360468